Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Kulzer GmbH, a subsidiary of Mitsui Chemicals, Inc., is a German company located in Hanau that manufactures and distributes dental prosthetics and similar products. Marc Berendes is the CEO, in this role since 2018.\nThe company says this about itself: Kulzer is one of the world��s leading dental companies with its headquarters in Hanau, Germany. As a trusted partner, the company supplies dentists and dental technicians with an extensive product range, covering cosmetic dentistry, tooth preservation, prosthetics, periodontology and digital dentistry.

Part of Einhorn Verwaltungsgesellschaft mbH, Heraeus Medical GmbH is a company headquartered in Wehrheim, Germany, that produces bone cement for joint fixation. Rolft Wetzel and Jan Rinnert are the current co-CEOs of the firm.

Pierrel S.p.A is a global service provider for the pharmaceutical, bio-pharmaceutical and life science industries. The Group, through its two business divisions, specializes in pharmaceutical production (Contract Manufacturing Division), and in the development, registration and licensing of new drugs and medical devices (Pharma Division).

Venus Remedies Ltd. engages in the manufacture and trade of pharmaceutical products. Its products include analgesic, analgesic and antipyretic, anti diabetic, antibiotic, cardiac, disinfectant and antiseptic, gastro therapy, hand sanitizer, hormone, iron supplement, neurology, oncology, pain management, respiratory, skin care, stress reliever, urology, vitamins/minerals/nutrients, and wound management. The company was founded by Pawan Chaudhary on September 15, 1989 and is headquartered in Panchkula, India.

Shandong Anxin Pharmaceutical Co., Ltd., established on 2019-09-02, Business scope includes pharmaceutical production,Sales(Does not contain Chinese herbal drinks and proprietary Chinese medicines)(The operating permit);Chemical raw materials(Does not contain dangerous goods)promotion of;Production of pharmaceutical excipients and intermediates,Sales;technology transfer,Technical Advisory Services;General cargo,dedicated transport(refrigeration)(The operating permit);Catering Services(The operating permit).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Cardeas Pharma is developing a novel antibiotic formulation of two drugs with synergistic activity against all relevant, highly resistant Gram-negative bacilli, including Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. In addition, this antibiotic formulation has activity on biofilms. The combination also has activity against Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA). This formulation is administered using a single-patient use, vibrating-plate nebulizer that is compatible with all ventilators. The nebulizer creates small, uniform aerosol droplets that deliver drug to the small airways and alveoli. Integration of this novel antibiotic formulation and device has the potential to achieve significant clinical outcomes relative to current standard therapy.

Aquarius Biotechnologies, Inc., a biotechnology company, develops proprietary drug delivery platform to improve existing drugs. It specializes in the fields of biotechnology, medicine, and pharmaceutical. The company was founded in 2013 and is based in Chicago, Illinois.

iNtRON Biotechnology, Inc. engages in the development of super-bacteria treatment, antibiotics alternatives, bio new drug, molecular diagnostics and artificial blood. Its products include anti-bacterial agents, identification kits, research reagents and kits. The company was founded on January 18, 1999 and is headquartered in Seongnam-si, South Korea.

Versitech Ltd. is a Hong Kong Chinese company located in Hong Kong and ultimately controlled by the Government of Hong Kong Special Administrative Region. The firm provides business services.

Aerogen, Inc. develops and manufactures aerosol products for treatment of respiratory disorders in the critical care setting. Its products include Aerogen Solo, Aerogen Ultra, Aerogen Pro, Pro-C controller, and USB controller. The company is headquartered in Deerfield, IL.

Lemonex Co., Ltd.is engaged in developing and commercializing cancer immunotherapeutic, antibody therapeutics and gene therapeutics. The company was founded on December 17, 2013 and is headquartered in Seoul, South Korea.

Mutabilis SA specializes in the discovery and development of anti-infective drugs. It focuses on novel therapeutic approaches for controlling severe and nosocomial infections. The firm offers antibacterial, vaccines, anti-infective agents, gram-positive & negative ant virulence lead series, specific antigens, and screening technologies for antibacterial and virulence targets. The company was founded in 2001 by Xavier Nassif and is headquartered in Romainville, France.

Guangzhou Institutes of Biomedicine and Health (GIBH)，(simplified Chinese: 中国科学院广州生物医药与健康研究院; traditional Chinese: 中國科學院廣州生物醫藥與健康研究院; pinyin: Zhōngguó Kēxué yuan guangzhou sheng wu yi yao yu jian kang yan jiu yuan) affiliated with the Chinese Academy of Sciences, is a government-sponsored scientific research institution with independent legal jurisdiction. GIBH was established by the Chinese Academy of Sciences, Guangdong Provincial Government and Guangzhou Municipal Government. The managerial mechanism of GIBH is the responsibility of Director-General, under the authority of the board of trustees.

Faron Pharmaceuticals Oy operates as a clinical stage biopharmaceutical company. It develops novel treatments for medical conditions with significant unmet needs caused by dysfunction of immune system. The firm currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Its Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. The company was founded by Juho Markku Jalkanen, Sirpa Tuulikki Jalkanen, Matti Esa Manner, Juha Peltola, Marko Salmi, Katriina Peltola and Maija-Leena Hollmen in 2003 and is headquartered in Turku, Finland.

ACS Dobfar is a privately held, chemical-pharmaceutical company that offers high quality pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms (oral and injectables). The company is committed to the production of Beta-lactam and Non Beta-lactam Anti-infectives, in particular Cephalosporins, Carbapenems, and Penicillins. It exports its products to more than 100 countries and employs more than 900 workers distributed over 6 production sites. ACS Dobfar was founded on 1973 and is headquartered in Agrate Brianza, Italy.

Part of Advanced Medical Solutions Group Plc, Advanced Medical Solutions Ltd. is a British company located in Winsford. The firm manufactures and distributes wound care, surgical and wound closure products. It was founded in 1991.\nThe company says this about itself: develops, manufactures and markets innovative products in the following areas: accelerating healing and managing wounds; minimising adverse surgical outcomes; and sealing and closing tissue. Principally, this includes the ActivHeal® range of advanced wound care and the LiquiBand range of topical skin adhesives. We manufacture and develop our wound care dressings at our world class facility in Winsford, Cheshire making it easy to respond to the needs of both the clinician and their patients here in the UK.

Cempra Pharmaceuticals, Inc. develops medicines for treating drug-resistant bacterial infections. The firm's antibacterial products, both in clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community. The company was founded by Prabhavathi B. Fernandes IN 2006 and is headquartered in Chapel Hill, NC.

Fujian Kanghong Biotechnology Co., Ltd., established on 2017-07-03, Business scope includes biotechnology research and development;Chemical raw materials,chemical preparation,Biopesticide API(Free of Hazardous Chemicals),Biopesticide formulation(Free of Hazardous Chemicals),food additives,Feed additives,Chinese Herbal Medicine,Chinese patent medicine,biopharmaceuticals,Research and development of pharmaceutical products,Manufacturing and sales;medicine,Chemical Products(Free of Hazardous Chemicals)technology development,technical consulting,technology transfer,Technical Services;medical products,food additives,Feed additives,Healthy food,medical instruments,Chemical Products(Free of Hazardous Chemicals)wholesale,Purchasing agency;Self-operated and agent import and export of various commodities and technologies,Except for the goods and technologies that the state restricts the company to operate or prohibits the import and export of.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Spexis Ltd. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of respiratory therapeutics. The firm focuses on rare, chronic respiratory diseases (CRD) and chronic lung infections in cystic fibrosis. Its product pipeline includes ColiFin, Inhaled Murepavadin, Balixafortide (POL6326), OMPTA, EBX-002, and POL6014 (Lonodelestat). The company was founded by Daniel Obrecht and Jean-Pierre Obrecht in 1996 and is headquartered in Allschwil, Switzerland.